ASX / MEDIA RELEASE ResApp Announces Expanded Research...

ASX / MEDIA RELEASE
ResApp Announces Expanded Research Collaboration with
Massachusetts General Hospital
Brisbane, Australia, 10 January 2017 -- ResApp Health Limited (ASX: RAP), the
developer of smartphone medical applications for the diagnosis and management of
respiratory disease, today announced that it has entered into a two-year expanded
research collaboration with Massachusetts General Hospital (MGH) alongside MGH’s
participation in ResApp’s SMARTCOUGH-C study. Working together, ResApp and
MGH will perform additional analysis of the SMARTCOUGH-C study data, use the
SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical
practice today and evaluate the efficacy of ResApp’s cough-based diagnostic test in
additional respiratory disease indications.
MGH is a 999-bed academic medical centre located in Boston, Massachusetts. MGH
has been named the number one healthcare organization for research by the Nature
Index which tracked the number of articles published in high-impact research
journals from February 2015 to January 2016 and has been among the top hospitals
each year on the U.S. News & World Report list of “America’s Best Hospitals.”
Dr. Peter Moschovis M.D., MPH will lead the team at MGH. Dr. Moschovis undertook
his specialist training at Harvard Medical School and has a joint appointment in
paediatrics and pulmonary/critical care at MGH. Dr. Moschovis is a global health
researcher in the Division of Global Health at MGH.
“We are delighted to expand our relationship with Dr. Moschovis and MGH beyond
the SMARTCOUGH-C study to diagnose additional diseases and to evaluate clinical
practices. The more broadly and effectively we apply ResApp’s technology with our
partners, the more rapidly we will integrate our diagnostic test into current clinical
practice,” said Tony Keating, CEO and Managing Director of ResApp Health.
- ENDS –